Pharmaceutical Executive Digest Europe - January 14, 2009 - (Page 7) Executive Profile a bigger impact on our sales than the credit crisis.” Nycomed and its partner Wyeth have now initiated their own generic version in the US, and, for the moment, the company continues to see better-than-expected sales in other territories. Also, Björklund reminds us, “a large part of pantoprazole’s sales — over 40% — is in markets where the patent has already expired or where there never was a meaningful patent.” But it is clearly time to look towards new products and new models to secure Nycomed’s future fortunes. One of the most promising products in the company’s pipeline is Daxas (roflumilast), a chronic pulmonary obstructive disease (COPD) treatment that showed very positive results in Phase III trials last year. Björklund explains: “We’re all very excited about Daxas because it is the first oral anti inflammatory treatment for COPD; it’s one of first new drugs developed for the disease in many, many years.” If it lives up to expectations, Daxas could indeed be huge — COPD is the fifth biggest killer disease in the world. Nycomed is planning to submit Daxas to the US and European regulatory authorities by the middle of 2009. “It’s not going to be as big as pantoprazole, but it will be a very big drug for us,” Björklund says. Big issues Nycomed’s ambitions are no longer focused on growing significantly larger. Indeed, in the present end-of-the-blockbuster climate, it looks like the smaller (and specialist) companies are better placed for survival. Björklund says that while the Altana acquisition gave Nycomed access to new territories and to a much larger R&D portfolio, he is well aware that “it’s actually an advantage not to be too big.” All the same, the company is now four times as big as it was four years ago, and, as CEO, he must have felt the challenges of that expansion as keenly as he saw the opportunities. “It has of course changed things,” he says. “The sheer size of it is different and the number of subsidiaries we have today is much larger, which of course means that my travelling has increased significantly.” He also realised that moving 9 Q&A Singapore Economic Development Board 11 STRATEGY FUNDAMENTALS Overcoming institutional theory jargon 13 CALENDAR The next few weeks’ pharma events 2 NEWS Major award for European healthcare agency
Table of Contents Feed for the Digital Edition of Pharmaceutical Executive Digest Europe - January 14, 2009 Pharmaceutical Executive Digest Europe - January 14, 2009 Contents News Brussels Report From the Editor Executive Profile Q&A Strategy Fundamentals Calendar Pharmaceutical Executive Digest Europe - January 14, 2009 Pharmaceutical Executive Digest Europe - January 14, 2009 - Contents (Page 1) Pharmaceutical Executive Digest Europe - January 14, 2009 - News (Page 2) Pharmaceutical Executive Digest Europe - January 14, 2009 - News (Page 3) Pharmaceutical Executive Digest Europe - January 14, 2009 - Brussels Report (Page 4) Pharmaceutical Executive Digest Europe - January 14, 2009 - From the Editor (Page 5) Pharmaceutical Executive Digest Europe - January 14, 2009 - Executive Profile (Page 6) Pharmaceutical Executive Digest Europe - January 14, 2009 - Executive Profile (Page 7) Pharmaceutical Executive Digest Europe - January 14, 2009 - Executive Profile (Page 8) Pharmaceutical Executive Digest Europe - January 14, 2009 - Q&A (Page 9) Pharmaceutical Executive Digest Europe - January 14, 2009 - Q&A (Page 10) Pharmaceutical Executive Digest Europe - January 14, 2009 - Strategy Fundamentals (Page 11) Pharmaceutical Executive Digest Europe - January 14, 2009 - Strategy Fundamentals (Page 12) Pharmaceutical Executive Digest Europe - January 14, 2009 - Calendar (Page 13)
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.